Taken together, further investigation of the molecular mechanisms underlying the development of α-synuclein pathology and PD pathogenesis (as well as other synucleinopathies) is necessary to identify new targets and design new treatment approaches. This evidence concerns the gene SNCA and Parkinson disease.